Theodore Pincus, MD
Rheumatology · Chicago, ILNPI 1700979747
Payments from drug & device makers
What this record shows
This record is dominated by royalties or licence payments: $502,627 of the $523,973 with a category attached, or 95.9%. Pfizer accounts for 76.4% of it on its own, with 4 other manufacturers making up the rest. 2025 is the largest year on record at $132,000, 2.3 times the $57,471 reported in 2019. Among rheumatology clinicians in IL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 24 payments — averaging $21,832 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$400K
- AbbVie$103K
- Gilead$14K
- Mallinckrodt Enterprises LLC$7K
- Pacira Therapeutics, Inc.$93
What the payments were for
- Royalty or licence$502,62796%
- Consulting fees$20,1254%
- Travel & lodging$7670%
- Food & beverage$4540%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 8 | $400,078 |
| AbbVie | 3 | $102,627 |
| Gilead | 1 | $13,875 |
| Mallinckrodt Enterprises LLC | 11 | $7,301 |
| Pacira Therapeutics, Inc. | 1 | $93 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$523,973 in reported general payments places this provider in the 95th percentile of 287 rheumatology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other rheumatology in Chicago
- Manish JainChicago$1.9M
- Eric RudermanChicago$440K
- Anisha DuaChicago$280K
- Arthur MandelinChicago$270K
- Robert WoodrickChicago$143K
- Maria SosenkoChicago$87K
- Ailda NikaChicago$74K
- Duncan MooreChicago$71K
- Timothy NiewoldChicago$65K
- Emem Adolf-UbokudomChicago$62K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.